KONINKLIJKE PHILIPS NV

Philips has launched the IntelliVue Patient Monitor 6000 Series, a new full monitoring solution tailored for rural hospitals, ambulatory surgery centers, and other U.S. healthcare segments. This series provides an accessible entry point to enterprise-grade capabilities at an affordable price, featuring flexible measurement expansion and scalable connectivity options. The solution aims to streamline operations, support clinical decision-making, and address budget and staffing challenges while preparing organizations for future connectivity needs.

Philips' Future Health Index 2026 reveals that AI is saving clinicians over 16 working days annually and increasing their capacity to see more patients, while also reducing stress and preventing medical errors. However, widespread adoption is hindered by inadequate training and fragmented IT infrastructure, with 70% of healthcare professionals reporting insufficient training. The report highlights the transformative potential of AI in care delivery but emphasizes the need for better implementation and support.

Royal Philips and WellSpan Health announced a landmark seven-year strategic alliance to advance diagnostics and imaging in community health. This collaboration includes a research and innovation strategy, the first of its kind for Philips with a U.S. community health system, focusing on validating new AI and digital tools to improve efficiency and co-develop future healthcare technology. Philips will also serve as WellSpan's preferred vendor for imaging modalities across its 12 hospitals and other facilities, ensuring consistent technology and care delivery.

Royal Philips has announced the exchange ratio for its 2025 dividend, setting it at 1 new common share for every 26.9341 existing common shares. This ratio was calculated to ensure a gross dividend in shares approximately equal to EUR 0.85, based on the volume-weighted average price of shares on Euronext Amsterdam. As a result, Philips will issue 19,964,655 new common shares, with 43.8% of shareholders electing for a cash dividend. The distribution of shares and cash payments will begin on June 3, 2026.

Koninklijke Philips NV announced it has received FDA 510(k) clearance for its Elevate Plus software for its EPIQ Elite and Affiniti ultrasound systems. This clearance brings advanced AI and automation capabilities to the flagship ultrasound systems, aiming to standardize routine exams, reduce the need for repeat scanning, and deliver more consistent, high-quality images faster. The AI-powered features, including Auto Measure Abdomen and integrated Koios AI decision support, are designed to streamline workflows, improve diagnostic confidence, and help care teams manage growing demand and staffing pressures.

Royal Philips announced the exchange ratio for its 2025 dividend, setting it at 1 new common share for every 26.9341 existing shares. This ratio, based on a volume-weighted average price of EUR 22.8640, results in a gross dividend of approximately EUR 0.85 per share. The company will issue 19,964,655 new common shares, with 43.8% of shareholders electing for a cash dividend. Delivery of new shares and cash payments will commence from June 3, 2026, bringing the total issued share capital to EUR 196,576,957.40, representing 982,884,787 common shares.

Royal Philips is showcasing new innovations at EuroPCR 2026 aimed at enhancing cardiac procedures by integrating imaging, physiology, and AI-enabled guidance. Key introductions include SmartIQ Technology, which reduces X-ray radiation dose by over 50%, IntraSight Plus for comprehensive diagnostic and treatment planning, and DeviceGuide, an AI-enabled solution for real-time device visualization. These advancements focus on improving efficiency, reducing radiation exposure for patients and staff, and supporting procedural confidence in complex interventions.

Royal Philips announced SmartIQ, a breakthrough coronary imaging technology for its Azurion image-guided therapy, designed to improve image quality while significantly reducing X-ray radiation and contrast exposure. The technology includes an ultra-low dose protocol that employs over 50% less X-ray radiation dose for coronary procedures. A clinical pilot study published in JSCAI showed SmartIQ scored higher on image quality and was preferred in most blinded comparisons. SmartIQ is CE-marked and available in Europe and selected markets, with an ongoing RADIQAL trial further assessing its impact.

Royal Philips announced that its consortium, including Cuviva and Vingmed, has been selected by Region Stockholm for a hospital-at-home initiative. This up to eight-year agreement, secured through a Karolinska University Hospital-led tender, will provide advanced remote monitoring for complex and chronic patients, supporting over 2 million people. The program aims to extend hospital-level care into patients' homes, leveraging Philips' monitoring expertise, Cuviva's digital platform, and Vingmed's clinical devices, thereby easing pressure on healthcare systems.

Royal Philips shareholders approved all proposals at the 2026 Annual General Meeting of Shareholders. Key approvals included the appointment of John DeFord as a new member of the Supervisory Board and the re-appointment of Paul Stoffels, Herna Verhagen, and Sanjay Poonen to the Supervisory Board. Additionally, Roy Jakobs was re-appointed as President/CEO and Chairman of the Board of Management, and the members of both boards were discharged. The company also thanked Marc Harrison, whose second term on the Supervisory Board ended.